PARAMEDIC2肾上腺素院外心脏骤停随机试验参与者的长期结局
PARAMEDIC2为实用性、个体随机、双盲对照试验,比较肾上腺素与安慰剂用于院外心脏骤停。8014例确认给药患者中,6个月良好神经功能结局肾上腺素组2.0% vs 安慰剂组1.5%(调整OR 1.35,95%CI 0.93-1.97);6个月生存2.9% vs 2.2%(OR 1.43,95%CI 1.05-1.96),12个月生存2.7% vs 2.0%(OR 1.38,95%CI 1.00-1.92)。3个月和6个月的认知、功能和生命质量指标两组间无强证据差异。结论为肾上腺素提高至12个月生存率,但未发现良好神经功能结局改善的证据。
要点
- 肾上腺素组6个月生存2.9% vs 安慰剂2.2%(OR 1.43,95%CI 1.05-1.96),12个月2.7% vs 2.0%(OR 1.38,95%CI 1.00-1.92)。
- 6个月良好神经功能结局肾上腺素组2.0% vs 安慰剂1.5%,调整OR 1.35(95%CI 0.93-1.97),无统计学显著改善。
- 3个月和6个月的认知、功能和生命质量指标两组均降低,但无强证据表明组间存在差异。
- 该试验为院外心脏骤停场景,肾上腺素与安慰剂个体随机双盲比较,结果支持肾上腺素改善长期生存但不改善神经功能结局。
适用人群与场景
- 院外心脏骤停患者,纳入PARAMEDIC2随机试验并确认给予试验药物的8014例患者。
- 场景为院前急救,干预为肾上腺素或安慰剂。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- PARAMEDIC2为实用性、个体随机、双盲、对照试验,含经济评估,8014例确认给药患者随机接受肾上腺素或安慰剂。
- 6个月生存肾上腺素组117(2.9%)vs 安慰剂组86(2.2%),OR 1.43(95%CI 1.05-1.96);12个月生存107(2.7%)vs 80(2.0%),OR 1.38(95%CI 1.00-1.92)。
- 3个月和6个月认知、功能及生命质量指标(Two Simple Questions、Mini Mental State Examination、Informant Questionnaire on Cognitive Decline Evaluation for Cardiac Arrest、Hospital Anxiety and Depression Scale、Post Traumatic Stress Disorder Check
证据类型、等级与局限
- 证据类型:实用性、个体随机、双盲、对照试验(RCT),含经济评估。
- 局限:原文未明确提及样本量、中心数、开放标签等设计局限;原文未提及证据等级或推荐强度。
对床旁实践的改变
- 对于院外心脏骤停患者,使用肾上腺素可提高至12个月生存率,但未发现良好神经功能结局改善的证据;临床决策需权衡生存获益与神经功能结局。
- 该结果适用于院外心脏骤停院前急救场景,不适用于其他场景或人群;原文未提及具体剂量、给药途径和频次。
指南或共识出处
- PARAMEDIC2随机试验(Prehospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug Administration in Cardiac Arrest),ISCRTN 73485024。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIMS: We recently reported early outcomes in patients enrolled in a randomised trial of adrenaline in out-of-hospital cardiac arrest: the PARAMEDIC2 (Prehospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug Administration in Cardiac Arrest) trial. The purpose of the present paper is to report long-term survival, quality of life, functional and cognitive outcomes at 3, 6 and 12-months.
METHODS: PARAMEDIC2 was a pragmatic, individually randomised, double blind, controlled trial with an economic evaluation. Patients were randomised to either adrenaline or placebo. This paper reports results on the modified Rankin Scale scores at 6-months, survival at 6 and 12-months, as well as other cognitive, functional and quality of life outcomes collected at 3 and 6 months (Two Simple Questions, the Mini Mental State Examination, the Informant Questionnaire on Cognitive Decline Evaluation for Cardiac Arrest, Hospital Anxiety and Depression Scale, the Post Traumatic Stress Disorder Checklist - Civilian Version, Short-Form 12-item Health Survey and the EuroQoL EQ-5D-5L).
RESULTS: 8014 patients were randomised with confirmed trial drug administration. At 6-months, 78 (2.0%) of the patients in the adrenaline group and 58 (1.5%) of patients in the placebo group had a favourable neurological outcome (adjusted odds ratio 1.35 [95% confidence interval: 0.93, 1.97]). 117 (2.9%) patients were alive at 6-months in the adrenaline group compared with 86 (2.2%) in the placebo group (1.43 [1.05, 1.96], reducing to 107 (2.7%) and 80 (2.0%) respectively at 12-months (1.38 [1.00, 1.92]). Measures of 3 and 6-month cognitive, functional and quality of life outcomes were reduced, but there was no strong evidence of differences between groups.
CONCLUSION: Adrenaline improved survival through to 12-months follow-up. The study did not find evidence of improvements in favourable neurological outcomes. (ISCRTN 73485024).
参考来源
- Haywood KL, Ji C, Quinn T, et al. Long term outcomes of participants in the PARAMEDIC2 randomised trial of adrenaline in out-of-hospital cardiac arrest. Resuscitation. 2021. PMID: 33524488. doi:10.1016/j.resuscitation.2021.01.019
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。